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Cells producing cytokines often express the receptor for the same cytokine, which makes them prone to autocrine signaling. How
cytokine release and signaling are regulated in the same cell is not understood. In this study, we demonstrate that signaling by
exogenous and self-synthesized inflammatory cytokine interleukin-6 (IL-6) within endosomal compartments acts as a cellular
brake that limits the synthesis of IL-6. Our data show that IL-6 is internalized by dendritic cells and signals from endosomal com-
partments containing the IL-6 receptor. Newly synthesized IL-6 also traffics via these endosomal compartments and signals in
transit to the plasma membrane. This allows activation of STAT3 which in turn limits toll-like receptor 4 stimulant lipopolysac-
charide (LPS) triggered transcription of IL-6. Long-term exposure to LPS removes this brake via inhibition of STAT3 by increased
expression of suppressor of cytokine signaling 3 and results in fully fledged IL-6 production. This transient regulation could pre-
vent excessive IL-6 production during early infections.
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Introduction
Interleukin-6 (IL-6) is the most pleiotropic cytokine known in
mammals (Ernst and Jenkins, 2004). It has both pro- and anti-
inflammatory properties and is involved in the pathogenesis of
all inflammatory diseases (Wolf et al., 2014; Garbers et al.,
2015; Tanaka et al., 2016). IL-6 can promote the activation,
growth, proliferation, and survival of many different cell types
(Hunter and Jones, 2015). IL-6 production by immune phago-
cytes is triggered by a wide range of stimuli, such as stress hor-
mones, cytokines, and pathogen recognition by toll-like
receptors (TLRs) (Dittrich et al., 1994). In healthy individuals,
blood levels of free IL-6 (i.e. not in complex with soluble IL-6
receptor) are in the low pg/ml range, depending on the assays
used because not every assay can distinguish between free and
complexed IL-6 (Helfgott et al., 1989; May et al., 1992, 1994;
Ndubuisi et al., 1998). In contrast, blood levels of IL-6 can
increase to ng/ml range in autoimmune diseases and to μg/ml
range during septic shock (Grossman et al., 1989; Waage et al.,
1989; Damas et al., 1992; Robak et al., 1998; Nowell et al.,
2003; Chaudhry et al., 2013; Shimamoto et al., 2013). In add-
ition, IL-6 levels correlate with tumor progression in many can-
cer types (Salgado et al., 2003; Yu et al., 2007; Xu et al., 2016).
IL-6 induces the development of Th17 cells while inhibiting dif-
ferentiation of regulatory T cells. These T cell subsets have key
functions in immune regulation: IL-17-producing Th17 cells pro-
tect against microbial infections but also contribute to the
pathogenesis of many autoimmune diseases, including multiple
sclerosis and rheumatoid arthritis, whereas regulatory T cells
limit excessive effector T cell responses (Kimura and Kishimoto,
2010). Differentiation of pathogenic Th17 cells mainly occurs by
presentation of IL-6 loaded onto the IL-6 receptor on the surface
of dendritic cells, in a process called trans-presentation (Heink
et al., 2017).
The IL-6 receptor consists of IL-6 receptor alpha (IL-6RA,
CD126, gp80) and the signal transducing subunit glycoprotein
130 (gp130, CD130) (Schaper and Rose-John, 2015). IL-6 first
binds to IL-6RA with a low affinity dissociation constant of
∼10 nM (Yamasaki et al., 1988; Dittrich et al., 1994). This com-
plex of IL-6 with IL-6RA in turn binds to two molecules of gp130
with two orders of magnitude higher affinity, resulting in a net
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dissociation constant in the pM to nM range (Zohlnho¨fer et al.,
1992; Dittrich et al., 1994; Hammacher et al., 1994). Following
oligomerization, Janus tyrosine kinases (JAK) phosphorylate the
intracellular tails of gp130 which in turn recruit and activate sig-
nal transducer and activator of transcription (STAT) and
mitogen-activated protein kinase (MAPK) signaling systems
(Ernst and Jenkins, 2004; Silver and Hunter, 2010). In addition
to the activation of STAT3 by phosphorylation of tyrosine 705,
its activity is further promoted by phosphorylation at serine 727
(Wen et al., 1995; Galdiero et al., 2006; Moravcova´ et al., 2016)
by the mammalian target of rapamycin (mTOR) (Yokogami et al.,
2000) or protein kinase C delta (PKCδ) (Bhattacharjee et al.,
2006). In contrast to IL-6RA, which is specific for IL-6, gp130 is
shared by all cytokines of the IL-6 family: IL-11, leukemia inhibi-
tory factor (LIF), oncostatin M (OsM), cardiotrophin-1 (CT-1), cil-
iary neurotrophic factor (CNTF), and cardiotrophin-like cytokine
(CLC) (Ernst and Jenkins, 2004). Whereas gp130 is ubiquitously
expressed in hematopoietic and non-hematopoietic cells, IL-6RA
is expressed only by a limited number of cell types, such as
hepatocytes and immune cells (Larregina et al., 1997;
McFarland-Mancini et al., 2010; Silver and Hunter, 2010; Wolf
et al., 2014; Garbers et al., 2015).
Interestingly, many leukocytes (monocytes, dendritic cells,
macrophages, B cells) that produce IL-6 also express IL-6RA
(Hwang et al., 2010), enabling autocrine signaling. Although
IL-6 was originally believed to promote activation and matur-
ation of dendritic cells (Jonuleit et al., 1997), it is increasingly
clear that IL-6 inhibits these processes via STAT3 activation
(Park et al., 2004; Yu et al., 2007; Melillo et al., 2010). In line
with this previously described inhibitory role, IL-6 knockout
mice show enhanced activation compared to wild-type (Wang
et al., 2004; Melillo et al., 2010). IL-6 also influences activation
of other immune cells as it, for instance, blocks the proliferation
of proinflammatory M1 macrophages in mice (Luig et al., 2015).
STAT3 activation interferes with TLR signaling, as pre-treatment
of dendritic cells with IL-6 reduces maturation triggered by lipo-
polysaccharide (LPS), a bacterial TLR4 stimulus, and leads to
decreased expression of the maturation markers CD86 and MHC
class II (Park et al., 2004). LPS in turn is well known to inhibit
tyrosine phosphorylation of STAT3 (pY-STAT3) (Meley et al.,
2017) and promote IL-6 synthesis by dendritic cells (van Bon
et al., 2010; Kumolosasi et al., 2014), raising the question of
how this cross-talk between STAT3 and TLR4 signaling would
affect cellular responses to IL-6 and LPS.
In this study, we investigated how signaling of self-
synthesized IL-6 affects the production of IL-6 by dendritic cells.
By microscopy, we show that newly synthesized IL-6 traffics
from the Golgi network to the plasma membrane via recycling
endosomes, a network of tubulovesicular compartments that
interconnects endocytic and exocytic trafficking pathways, as
previously shown for macrophages (Manderson et al., 2007)
and dendritic cells (Verboogen et al., 2018). We hypothesized
that newly synthesized IL-6 in transit to the plasma membrane
could signal from these recycling endosomal compartments,
since IL-6 has been described to signal from endosomes in
hepatocytes (Shah et al., 2006; Xu et al., 2007; German et al.,
2011). Indeed, we found that in dendritic cells pY-STAT3 signal-
ing is initiated by binding of both internalized IL-6 and newly
synthesized IL-6 to IL-6RA within intracellular compartments. This
signaling results in a negative feedback loop and acts as a brake
limiting IL-6 synthesis. However, long-term exposure to LPS
releases this brake, as pY-STAT3 is inhibited by a LPS-induced
increase of expression of suppressor of cytokine signaling 3
(SOCS3), a previously described suppressor of STAT3 signaling
(Croker et al., 2003, 2012; Lang et al., 2003), and this allows full
IL-6 production. Thus, our data show that self-signaling by newly
synthesized IL-6 limits the production of IL-6 during short-term
exposure to the inflammatory stimulus LPS. This mechanism
might serve to restrain IL-6 responses during early infection and
sepsis.
Results
Cross-inhibition of IL-6 and LPS signaling in dendritic cells
We first confirmed that the IL-6 receptor is expressed by den-
dritic cells. Reverse transcription (RT)-PCR, western blot,
and flow cytometry showed that IL-6RA is expressed by human
CD1c+ myeloid and BDCA4+ plasmacytoid dendritic cells (mDC
and pDC) isolated from the blood of healthy donors (Figure 1A
and Supplementary Figure S1A–E). IL-6RA is also expressed by
dendritic cells differentiated from human blood-isolated mono-
cytes (moDCs) by granulocyte macrophage colony-stimulating
factor (GM-CSF) and IL-4, as reported previously (Meley et al.,
2017). Moreover, mouse bone marrow-derived dendritic cells
(BMDCs) differentiated by either GM-CSF or fms-related tyrosine
kinase 3 ligand (FLT3L) expressed IL-6RA, as reported previously
(Hwang et al., 2010), as well as the murine macrophage cell line
RAW264.7. IL-6RA can be expressed as a long transmembrane iso-
form and as a short soluble isoform lacking its transmembrane
helix and cytoplasmic domain (Wolf et al., 2014; Garbers et al.,
2015). Soluble IL-6RA can also be produced by shedding of
the long isoform of IL-6RA from the cell membrane (Mu¨llberg
et al., 1993, 1994) by metalloproteases ADAM10 and ADAM17
(Matthews et al., 2003; Yan et al., 2016; Zunke and Rose-John,
2017). For western blot, we used an antibody recognizing the cyto-
plasmic C-terminal tail of IL-6RA, meaning that only the full-length
membrane bound form of IL-6RA was detected. However, tran-
scription of the short isoform was also detected by RT-PCR with
isoform-specific primers (Horiuchi et al., 1994) (Supplementary
Figure S1C). Moreover, the short soluble isoform of IL-6RA was
detected in the supernatant of moDCs by ELISA, as recently shown
(Meley et al., 2017), and this was independent of the presence of
LPS (Supplementary Figure S1F).
Although the expression levels of IL-6RA varied widely among
donors/mice, repeats and conditions, western blot experiments
showed that IL-6RA expression did not change significantly after
stimulation with LPS up to 24 h in GM-CSF and FLT3L-differentiated
BMDCs and RAW264.7 macrophages (Figure 1A and Supplementary
Figure S1A). Similarly, western blot and flow cytometry experiments
revealed that IL-6RA expression did not change significantly in pri-
mary mDCs after overnight stimulation with LPS or with a
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combination of the TLR3 agonist polyinosinic:polycytidylic acid
(poly(I:C)) and the TLR7/8 agonist R848, nor in plasmacytoid den-
dritic cells stimulated with the TLR9 agonist CpG-C (Figure 1A;
Supplementary Figure S1A and D).
For the rest of the experiments, we focused on moDCs, a
widely used model system for immune cell function capable of
producing large amounts of IL-6 (van Bon et al., 2010;
Verboogen et al., 2018). MoDCs do not only express IL-6RA but
also the signaling co-receptor gp130 (Figure 1A; Supplementary
Figure S1A, E–G). The soluble form of gp130, which is produced
by shedding of full-length gp130 from the cell membrane, could
also be detected in the supernatant by ELISA after 24 h incuba-
tion with LPS (Supplementary Figure S1H). For some donors, LPS
resulted in lower levels of IL-6RA and gp130, but this was not
consistent as no changes were observed for other donors, and,
although there was a trend towards overall lower IL-6RA and
gp130 levels, the donor-averaged cellular levels of gp130 and
IL-6RA did not significantly change upon LPS stimulation
(Figure 1A; Supplementary Figure S1A, D–H). In line with this,
comparison of the profiles of the IL-6RA bands of the western
blots suggested that the glycosylation states of IL-6RA did not
significantly change upon LPS treatment (Supplementary
Figure S1I). These results contrast the observations by Meley
et al. (2017) that short-term (up to 8 h) LPS treatment resulted in
a slight decrease of IL-6RA levels whereas longer incubations
result in higher levels of IL-6RA, and gp130 levels decreased
Figure 1 LPS induces STAT3 tyrosine phosphorylation but inhibits IL-6-mediated STAT3 tyrosine phosphorylation in dendritic cells. (A) IL-
6RA expression by western blot for mDC with or without overnight stimulation with LPS or a combination of Poly(I:C) and R848, for pDC, and
for moDCs, RAW264.7, and murine GM-CSF, and FLT3L-differentiated BMDCs stimulated with LPS for the indicated times. GAPDH is loading
control. Quantification for multiple donors is shown in Supplementary Figure S1A. (B) STAT3 tyrosine 705 phosphorylation (pY-STAT3) by
western blot. MoDCs were incubated with the indicated IL-6 concentrations for 20 min with or without 4 h LPS pre-incubation. α-tubulin is
loading control. Results from the other three donors are shown in Supplementary Figure S2A. (C) Quantification of pY-STAT3/STAT3 in B
(error bars represent SEM for four donors; see Supplementary Figure S2A). Data were normalized to the highest ratio of pY-STAT3 over
STAT3 per donor. (D) pY-STAT3 by western blot. moDCs were incubated with LPS for 4, 8, or 24 h (data from individual donors are shown).
(E) pY-STAT3 of moDCs incubated with the indicated LPS concentrations for 4 h by western blot. (F) IL-6 concentration in the medium col-
lected from the cells in E by ELISA.
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strongly upon LPS treatment, possibly because of the large donor
variation or the source of LPS used. IL-6RA and gp130 are capable
of forming a signaling-competent complex, as culturing in the pres-
ence of IL-6 concentrations above 0.15 ng/ml resulted in tyrosine
phosphorylation of STAT3 (pY-STAT3, Tyr705) in a concentration-
dependent manner (Figure 1B and C; Supplementary Figure S2A
and B). In contrast, serine phosphorylation of STAT3 (pS-STAT3,
Ser727) was already observed in the absence of IL-6 and only
increased at the highest concentration of IL-6 tested (15 ng/ml;
Supplementary Figure S2B).
Next, we tested whether LPS stimulation of the moDCs would
block STAT3 activation, as has been described (Niemand et al.,
2003; Bode et al., 2012; Meley et al., 2017). Indeed, LPS par-
tially blocked STAT3 activation, as levels of pY-STAT3 by IL-6
were reduced when we pre-cultured the cells for 4 h with LPS
prior to the addition of IL-6 (∼90% reduction for 15 ng/ml IL-6
compared to without LPS) (Figure 1B and C; Supplementary
Figure S2A and B). In contrast, LPS did not affect serine phos-
phorylation for all concentrations of IL-6 tested, except for the
highest concentration of 15 ng/ml IL-6, where we observed a
slight reduction of serine phosphorylation (Supplementary
Figure S2B). Tyrosine phosphorylation of STAT3 in the presence
of LPS was no longer dependent on the concentration of IL-6,
but already 10 ng/ml LPS (i.e. the lowest concentration of LPS
tested) without IL-6 resulted in tyrosine phosphorylation of
STAT3 in a time-dependent fashion, albeit with slower kinetics
than IL-6-mediated pY-STAT3 phosphorylation (Figure 1D and E),
and as previously shown (Meley et al., 2017). This increase was
likely caused by autocrine signaling, as LPS promoted transcrip-
tion of IL-6 (Supplementary Figure S2C) resulting in IL-6 produc-
tion to a final concentration of approximately 3 ng/ml
(Figure 1F). These results demonstrate that already low concen-
trations of LPS partially, but not completely, block activation of
pY-STAT3 by IL-6. In order to further investigate the molecular
basis for this LPS block of pY-STAT3 signaling, we looked into
SOCS3 activation, a well-known negative regulator of STAT3
(Croker et al., 2003, 2012; Lang et al., 2003). Our data show
that LPS stimulation resulted in higher transcription and protein
levels of SOCS3 (Figure 2A–C), suggesting a role of this protein
at the intersection between TLR4 and IL-6RA signaling. Moreover,
pY-STAT3 levels were clearly reduced by culturing in the pres-
ence of MG132, a proteasome inhibitor that prevents degrad-
ation of SOCS3 (Figure 2D and E).
We then investigated cross-talk in the reverse direction, thus
whether STAT3 activation would inhibit TLR responses, because IL-6
is known to inhibit dendritic cell maturation via STAT3 (Schindler
et al., 1990; Park et al., 2004; Yu et al., 2007). Since TLR signaling
promotes IL-6 synthesis (Supplementary Figure S2C), autocrine
activation of STAT3 by IL-6 might lead to a negative feedback loop
limiting cellular IL-6 production. To address this possibility, we per-
formed siRNA gene silencing of IL-6RA (siIL-6RA) in moDCs and
used non-targeting siRNA as a negative control (siCntrl). The levels
of IL-6RA knockdown were sufficient (>95% by western blot,
flow cytometry, and immunofluorescence microscopy) (Figure 2F;
Supplementary Figure S3A and B) to attain ∼80% blockage of
IL-6 induced pY-STAT3 signaling (Figure 2G and H). Culturing
IL-6RA-silenced moDCs in the presence of LPS for 4 h (i.e. the
time after which we observed pY-STAT3 signaling; Figure 1D)
increased both IL-6 transcription (by qPCR) and protein production
(by ELISA) by ∼2–3 folds compared to siCntrl (Figure 2I and J).
These differences in IL-6 transcription and secretion disappeared
after prolonged culturing with LPS (8 h) (Figure 2J and
Supplementary Figure S3C), likely because of the refractory phase
in which pY-STAT3 signaling is disabled by increased cellular
levels of SOCS3 (Figure 2). Thus, LPS inhibits IL-6-induced
pY-STAT3 signaling, whereas IL-6 reduces LPS-induced IL-6 pro-
duction, suggesting that there is a mutual cross-inhibition between
the IL-6 and the LPS signaling pathways in dendritic cells.
IL-6 signals from intracellular compartments
In hepatocytes, IL-6 predominantly signals from intracellular
compartments of endosomal nature (Shah et al., 2006; Xu et al.,
2007; German et al., 2011; Schmidt-Arras et al., 2014). We
determined the subcellular localization of IL-6RA signaling in
dendritic cells. First, we measured the fraction of IL-6RA present
at the cell membrane and at intracellular organelles. MoDCs
were immunostained with a monoclonal antibody recognizing
the extracellular domain of IL-6RA both under permeabilizing
and non-permeabilizing conditions and analyzed these stainings
by flow cytometry. About 35% of IL-6RA was present at the plas-
ma membrane, similar to the transferrin receptor (TfR) which
also cycles via recycling endosomes to the plasma membrane
(Figure 3A and Supplementary Figure S4A). Transmission elec-
tron microscopy experiments with immuno-gold antibody-conju-
gate uptake confirmed the presence of IL-6RA at intracellular
compartments (Figure 3B and Supplementary Figure S4B). We
performed immunofluorescence microscopy experiments to char-
acterize the type of intracellular compartments where IL-6RA
was residing. Because the signal of our IL-6RA antibody was too
weak to resolve intracellular compartments (Supplementary
Figure S3B), we visualized IL-6RA by overexpression of a con-
struct coding for IL-6RA C-terminally fused to the fluorescent
reporter protein mCherry. Fusion constructs of IL-6RA C-termin-
ally conjugated to fluorescent proteins have been used previ-
ously to study IL-6RA trafficking and shedding (Chalaris et al.,
2010). By immunofluorescence labeling, we observed localiza-
tion of IL-6RA-mCherry at the plasma membrane and at an intra-
cellular pool that overlapped with compartments positive for the
early/recycling endosomal SNARE protein VAMP3, the early/late
endosomal SNARE protein VAMP8 (Antonin et al., 2000), the
trans-Golgi marker TGN38 (Murray et al., 2005), the recycling
endosomal marker TfR, and less with the late endosomal/lyso-
somal marker LAMP1 and the early endosomal marker EEA1
(Figure 3C and D). These results indicate that IL-6RA traffics
to the plasma membrane, the Golgi apparatus, recycling endo-
somes, and late endosomes/lysosomes.
Since our data show that the majority of IL-6RA locates at
intracellular compartments in dendritic cells, and since IL-6RA
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signaling in hepatocytes is known to occur from intracellular
compartments (Shah et al., 2006; Xu et al., 2007; German et al.,
2011), we then tested for intracellular signaling of IL-6RA.
Quantitative immunofluorescence experiments showed that
exogenous IL-6 was taken up by the cells in a concentration-
dependent manner (Figure 4A), with a similar concentration
dependency as pY-STAT3 activation (Figure 1C). Although IL-6
exposure resulted in lower cellular levels of IL-6RA (Figures 2G
Figure 2 Cross-inhibition of IL-6 and LPS signaling in dendritic cells. (A) Quantification of SOCS3 mRNA levels in moDCs upon 4 h incubation
in the presence or absence of LPS and/or IL-6. (B and C) moDCs were exposed to 0, 4, or 24 h LPS stimulation. The 0 h exposure to LPS
was a quick wash in LPS-containing culture medium (<10 sec). SOCS3 protein levels (B) and tyrosine phosphorylated (Tyr705) pY-STAT3
over total STAT3 levels (C) were examined by western blot and quantified. For each donor, the relative levels were normalized to that of 0 h
exposure to LPS stimulation. Representative blots (from the same donor) are shown and data from individual donors are shown in the
graph. (D and E) moDCs were exposed to 0, 4, or 24 h LPS stimulation in the presence of the proteasome inhibitor MG132. SOCS3 levels (D)
and pY-STAT3/STAT3 levels (E) were examined by western blot and then quantified. For each donor, the relative levels were normalized to
that of 0 h LPS stimulation from B. Representative blots (from the same donor as shown in B and C) are shown and data from individual
donors are shown in the graph. (F) Western blot showing IL-6RA levels in moDCs upon siRNA silencing of IL-6RA (siIL-6RA) and non-
targeting siRNA (siCntrl). Bar graph: quantification (error bars represent SEM for six donors). (G) pY-STAT3 and IL-6RA levels in moDCs upon
siIL-6RA and siCntrl treatment in the absence or presence of exogenous IL-6 for the indicated times. (H) Quantification of pY-STAT3/STAT3
in G. Data shown were from individual donors, normalized to the maximum pY-STAT3/STAT3 ratio for each donor. (I) IL-6 secretion by 4 h
LPS-stimulated moDCs with or without siIL-6RA by ELISA (data from individual donors are shown). (J) IL-6 mRNA transcription in moDCs with
or without siIL-6RA upon 4 or 8 h LPS incubation by qPCR.
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and 4B), as reported previously (Meley et al., 2017), we could
not detect significant breakdown of exogenous IL-6 by the den-
dritic cells by quantitative ELISA (Supplementary Figure S5A–C).
Although this apparent absence of IL-6 degradation might be
caused by a too low sensitivity of the used assay, it at least
shows that under our experimental conditions cellular breakdown
did not have a measurable impact on extracellular IL-6 concentra-
tions. IL-6 uptake by dendritic cells is important for signaling,
because IL-6-dependent activation of pY-STAT3 could be almost
completely blocked with the dynamin inhibitor hydroxy-dynasore
(Figure 4C and Supplementary Figure S5D). Hydroxy-dynasore
treatment increased IL-6RA localization at the plasma membrane
by ∼50% (Figure 4D), indicating that IL-6RA cycles via the plasma
membrane to intracellular compartments. These findings support
the signaling of IL-6 from intracellular compartments in dendritic
cells, in a similar way as in hepatocytes, where IL-6 and IL-6RA
are endocytosed in a dynamin-dependent manner and inhibition
of dynamin results in impaired pY-STAT3 activation (Dittrich
et al., 1994; Thiel et al., 1998; Shah et al., 2006; Xu et al., 2007;
Schmidt-Arras et al., 2014).
The endosomal signaling of IL-6RA was further supported by
live cell fluorescence microscopy experiments of dendritic cells
expressing STAT3 fused to GFP (STAT3-GFP) which is retained at
the nucleus upon activation (Shah et al., 2006; Ng et al., 2014).
STAT3-GFP was co-expressed with a mCherry-tagged variant of
the endocytic cargo adaptor Epsin 2 (Epsin2-mCherry) (Taylor
et al., 2011). Overexpression of Epsin 2 acts as a dominant nega-
tive and blocks clathrin-mediated endocytosis by misguiding epi-
dermal growth factor receptor substrate 15 and adapter protein
2 to overexpression foci (Rosenthal et al., 1999). Supporting a
role for endocytosis in IL-6 signaling, the IL-6-induced transloca-
tion of STAT3-GFP to the nucleus was ∼2-fold reduced in
Figure 3 IL-6RA localizes at the plasma membrane, Golgi, and endosomes in dendritic cells. (A) Flow cytometry of moDCs immunostained
for IL-6RA with (total) or without (surface) permeabilization. Geometric mean fluorescence intensities (gMFI) for individual donors are shown
(isotype subtracted). (B) Transmission electron microscopy image of endocytosed antibody against IL-6RA labeled with Protein A-gold nano-
particles. Pink arrowheads indicate gold nanoparticles. Scale bar, 200 nm. (C and D) Confocal images (C) and quantification by Pearson cor-
relation coefficients (D) of moDCs expressing IL-6RA fused to mCherry (magenta in merge; IL-6RA-mCherry) and immunolabeled for VAMP8,
VAMP3, EEA1, LAMP1, TfR, or TGN38 (green). DAPI is in blue in merge. Graphs: fluorescence cross-sections as indicated. Yellow regions:
overlap of IL-6RA-mCherry with organellar markers. Representative cells from multiple donors are shown (>7 cells/donor). Scale bar, 20 μm.
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dendritic cells expressing Epsin 2-mCherry compared to the con-
trol of mCherry alone (Figure 4E–G; Supplementary Movies S1
and S2). In some cells, we observed punctuated signals of
STAT3-GFP in the cytosolic region (i.e. control condition of
mCherry in Figure 4E), which might be caused by local STAT3
activation at endosomes, as reported in Hep3B cells (Xu et al.,
2007). These results show that IL-6RA signals from intracellular
compartments, and we next addressed whether de novo synthe-
sized IL-6 in transit to the plasma membrane could also signal
from these sites.
Intracellular signaling of newly synthesized IL-6 prior to
secretion
In macrophages and dendritic cells, newly synthesized IL-6
does not traffic directly from the Golgi apparatus to the plasma
membrane, but is instead routed via recycling endosomes that
partially overlap with TfR and VAMP3 (Manderson et al., 2007;
Verboogen et al., 2018). We performed fluorescence microscopy
experiments to characterize the organelles of IL-6 trafficking.
However, we only observed a very low signal of IL-6 in LPS-
stimulated moDCs by immunofluorescence microscopy and flow
Figure 4 Endocytosis of IL-6 is required for paracrine STAT3 signaling. (A) MoDCs incubated with increasing concentrations of IL-6 for
20 min and immunostained for intracellular IL-6 (green) were imaged by confocal microscopy. DAPI is in blue. Yellow arrowheads indicate
IL-6-positive cells. Graph: quantification of IL-6 signals (mean ± SEM from three donors). Scale bar, 10 μm. (B) Quantification of IL-6RA
upon incubation with IL-6 for the indicated times by western blot (see also Figure 2G). Data were normalized to the highest IL-6RA band
intensity per donor. α-tubulin is loading control. (C) STAT3 tyrosine 705 phosphorylation (pY-STAT3) of moDCs incubated with or without
hydroxy-dynasore and/or 15 ng/ml IL-6. Graph: quantification for three different donors (mean ± SEM). Data were normalized to the highest
pY-STAT3/STAT3 ratio per donor. (D) Flow cytometry of moDCs incubated with or without hydroxy-dynasore and immunostained for surface
IL-6RA. gMFI of different donors are shown (isotype subtracted). (E) Fluorescence microscopy images of moDCs transfected with STAT3-GFP
(green in merge) and only mCherry or Epsin2-mCherry (magenta in merge) and stimulated with IL-6 for 20 min. Scale bar, 20 μm (see also
Supplementary Movies S1 and S2). (F) Quantification of STAT3-GFP retention at the nucleus following IL-6 stimulation in E (mean ± SEM for
80 cells from four donors). (G) Quantification of STAT3-GFP retention at the nucleus at 20 min after IL-6 stimulation for only mCherry (cntrl)
or Epsin2-mCherry (from F; individual donor averages shown for 20–23 cells/donor).
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cytometry, and this signal was only observable at 4 h after LPS
stimulation (Supplementary Figure S6A–C). As a positive control,
inhibition of ER-Golgi trafficking with Brefeldin A (Bueno et al.,
2001; Manderson et al., 2007) resulted in accumulation of IL-6
within the cells (Supplementary Figure S6A–C). SiRNA silencing
of IL-6RA in moDCs, which blocks pY-STAT3 activation and
results in higher IL-6 production (Figure 2F–J; Supplementary
Figure S6E), also increased the intracellular accumulation of
endogenous IL-6 compared to siCntrl by immunofluorescence
microscopy and flow cytometry (Figure 5A and B). These results
indicate that newly synthesized IL-6 does not accumulate within
the majority of moDCs but is mostly secreted from these cells, as
we reported previously (Verboogen et al., 2018) and has also
been described for peripheral blood mononuclear cells (Schindler
et al., 1990). In order to resolve the organelles involved in IL-6
trafficking, we increased the intracellular presence of IL-6 by
overexpression of a construct coding for human IL-6 fused to GFP
(IL-6-GFP). This strategy of overexpression of GFP-tagged IL-6 has
been used previously to visualize intracellular trafficking of IL-6
(Manderson et al., 2007; Verboogen et al., 2018). We stimulated
IL-6-GFP-transfected moDCs for 4 h with LPS and subsequently
determined the subcellular localization of IL-6-GFP by immuno-
fluorescence labeling with the same panel of organellar markers
as we used previously for IL-6-RA (Figure 3C). Partial overlap of
the IL-6-GFP signal was observed with the Golgi marker TGN38,
the early/recycling endosomal markers EEA1 and VAMP3, the
Figure 5 IL-6 is secreted via the Golgi apparatus and endosomes in dendritic cells. (A) Confocal micrographs of moDCs with siIL-6RA or con-
trol siRNA (siCntrl) and immunostained for IL-6 (green in merge). DAPI is in blue in merge. Yellow arrowheads indicate IL-6-positive cells.
Graph: quantification of IL-6 fluorescence for individual donors. Scale bar, 50 μm. (B) Flow cytometry analysis of intracellular IL-6 accumula-
tion in moDCs after siCntrl or siIL-6RA incubated with LPS for the indicated times (four individual donors; mean ± SEM; normalized to
Brefeldin A-treated samples, see Supplementary Figure S6D). (C and D) Confocal images (C) and quantification by Pearson correlation coeffi-
cients (D) of moDCs expressing IL-6 fused to GFP (green in merge; IL-6-GFP) and immunolabeled for VAMP8, VAMP3, EEA1, LAMP1, TfR, or
TGN38 (magenta). DAPI is in blue in merge. Graphs: fluorescence cross-sections as indicated. Yellow regions: overlap of IL-6-GFP and orga-
nellar markers. Representative cells from multiple donors are shown (>7 cells/donor). Scale bar, 20 μm.
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late endosomal/lysosomal markers VAMP8 and LAMP1, and the
TfR (Figure 5C and D). These results confirm that IL-6-GFP is
secreted via the Golgi network and early/recycling endosomes,
as previously reported for macrophages and dendritic cells
(Manderson et al., 2007; Verboogen et al., 2018).
We then determined whether IL-6 would traffic via the same
intracellular compartments as IL-6RA. Clear overlap of the IL-6-
GFP and IL-6RA-mCherry signals was observed in moDCs co-
transfected with both proteins, both in the absence and presence
of LPS (Figure 6A), and as reported previously for BMDCs (Heink
et al., 2017). Live cell time-lapse total-internal reflection fluores-
cence (TIRF) microscopy experiments confirmed that IL-6-GFP and
IL-6RA-mCherry co-migrated to the plasma membrane (Figure 6B
and Supplementary Movie S3). These experiments suggest that
newly synthesized IL-6 in transit to the plasma membrane could
encounter IL-6RA in intracellular compartments, which would
enable auto-activation of STAT3. We performed flow chamber
experiments to determine whether newly synthesized IL-6, and
possibly other STAT3 activating factors such as IL-10 (Melillo
et al., 2010), in transit to the plasma membrane would suffice for
activation of STAT3. We kept moDCs under a constant flow,
thereby continuously refreshing the LPS-supplemented medium
and flushing away all secreted cytokines (Figure 6C). Under our
experimental conditions, the concentration of IL-6 in the flow
chamber remained well below 0.05 ng/ml which is far too low for
STAT3 activation in the absence of LPS (Figures 1B, C and 6C).
Nevertheless, LPS-induced pY-STAT3 activation could be detected
under flow (Figure 6D), supporting the existence of self-signaling
of newly synthesized IL-6 (and other factors) from intracellular
compartments within the cells. To confirm this self-signaling of
Figure 6 Signaling of newly synthesized IL-6 in transit to the plasma membrane. (A) Confocal images of moDCs co-expressing IL-6 fused to
GFP (green in merge; IL-6-GFP) and IL-6RA fused to mCherry (magenta; IL-6RA-mCh) stimulated without or with LPS for 4 h. DAPI is in blue
in merge. Graphs: fluorescence cross-sections as indicated. Yellow regions: overlap of IL-6-GFP and IL-6RA-mCherry. Bar graph: quantifica-
tion of overlap by Pearson correlation coefficient (four donors; >7 cells/donor). Scale bar, 20 μm. (B) Stills from time-lapse TIRF microscopy
of moDC overexpressing IL-6-GFP (green in merge) and IL-6RA-mCherry (magenta). Details of two exocytosis events indicated by the yellow
arrowheads are shown. Graphs: quantification of the signals over time. Scale bar, 10 μm. Yellow regions: occurrence of exocytosis events
(see also Supplementary Movie S3). (C) Scheme of the experimental setup for STAT3 activation under constant medium flow with or without
LPS for 4 h. The graph shows the IL-6 concentrations in the supernatant from moDCs cultured in the presence or absence of LPS and with or
without flow by ELISA. (D) Quantification of pY-STAT3 activation from moDCs in C for individual donors (mean ± SEM). Data were normalized
to the highest pY-STAT3/STAT3 ratio per donor. (E) Quantification of VAMP3 after siRNA gene silencing (siV3) or non-targeting siRNA control
(siCntrl) with or without 4 h LPS stimulation (mean ± SEM from 3 donors). GAPDH: loading control. (F) Quantification by western blot of
pY-STAT3 activation after siV3 incubated with or without LPS for 4 h (mean ± SEM from 3 donors). (G) Quantification of pY-STAT3 activation
upon incubation with 1 μg/ml LPS for 4 h or 15 ng/ml IL-6 for 20 min, in the absence or presence of an IL-6-neutralizing antibody (anti-IL-6)
or IgG control (IgG-cntrl) (mean ± SEM from three donors). Representative western blots are shown.
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newly synthesized IL-6, we performed siRNA knockdown of the
SNARE protein VAMP3. VAMP3 mediates secretion of IL-6 and its
knockdown results in impaired IL-6 secretion (Manderson et al.,
2007; Boddul et al., 2014; Verboogen et al., 2017). VAMP3
knockdown also results in increased LPS-induced pY-STAT3 levels
(Figure 6E and F), in line with intracellular self-signaling of newly
synthesized IL-6. Finally, we performed experiments with an IL-6
neutralizing antibody that blocks IL-6 binding to the receptor
(Figure 6G). Whereas this antibody could completely block
pY-STAT3 activation triggered by extracellular IL-6, LPS-induced
pY-STAT3 phosphorylation was not affected compared to condi-
tions without antibody or isotype control (Figure 6G). Together,
these findings support a model where newly synthesized IL-6
activates pY-STAT3 in transit to the plasma membrane from intra-
cellular compartments.
Discussion
Endosomal signaling is emerging as an important principle for
many different receptors, including receptor tyrosine kinases,
insulin G protein-coupled receptors, and TLRs (Murphy et al.,
2009; Platta and Stenmark, 2011). In this study, we show that
although IL-6RA appears at the plasma membrane, IL-6-mediated
tyrosine phosphorylation of STAT3 mainly occurs from intracellu-
lar compartments. This is in line with the finding that IL-6 and
IL-6RA co-localize in intracellular compartments of BMDCs (Heink
et al., 2017). In the hepatocyte cell lines HepG2 and HepB3,
endosomal signaling of IL-6 (Shah et al., 2006; Xu et al., 2007;
German et al., 2011; Schmidt-Arras et al., 2014) is proposed to
promote STAT3-induced transcription by reducing the distance
that STAT3 has to travel to the nucleus (German et al., 2011). A
second potential role of endosomal signaling is that it might
increase control over signaling, as receptors can be readily sorted
to the lysosome for degradation or back to the plasma membrane
for re-sensitization for the corresponding stimulus (Platta and
Stenmark, 2011). In hepatocytes, IL-6 bound to IL-6RA and gp130
is internalized via the constitutive internalization of gp130
(Dittrich et al., 1994; Thiel et al., 1998) and the IL-6 receptor com-
plex is subsequently degraded leading to a downregulation of
the IL-6 receptor (Zohlnho¨fer et al., 1992; Wang and Fuller, 1994;
Heinrich et al., 1998; Blanchard et al., 2001). Also in dendritic
cells, our data show that cellular levels of IL-6RA are reduced
upon IL-6 stimulation, in line with previous findings (Meley et al.,
2017), although we did not find evidence that breakdown of IL-6
itself resulted in a measurable reduction of extracellular IL-6
levels at our experimental conditions. Less efficient IL-6 degrad-
ation in dendritic cells compared with hepatocytes might well be
physiological, since dendritic cells are major producers of IL-6
(Daudelin et al., 2013; Heink et al., 2017; Verboogen et al.,
2017), whereas the liver is the major organ for removing IL-6
from circulation (Castell et al., 1990; Sonne et al., 1990).
A third potential role of intracellular interactions between IL-6
and IL-6RA is that it might facilitate organellar trafficking of IL-6.
Our data indicate that these interactions already might occur
within the Golgi and recycling endosomes. In macrophages,
immuno-gold labeled IL-6 appeared consistently in close proximity
to the luminal face of the membrane of recycling endosomes
(Manderson et al., 2007), suggesting membrane association pos-
sibly by interactions with IL-6RA. IL-6RA thereby might act as an
adapter molecule ensuring proper sorting of IL-6 to the correct
target organelles. Such a mechanism would be reminiscent of
the trafficking of newly formed IL-4 by the IL-4 receptor in eosi-
nophils (Spencer et al., 2006). The trafficking of IL-6 by IL-6RA
could explain how IL-6 can traverse through sub-compartments
of recycling endosomes (Murray and Stow, 2014). This compart-
mentalization of recycling endosomes is the key to their sorting
function, as it allows to direct cargo molecules in different direc-
tions, e.g. to the plasma membrane, to the Golgi apparatus, or
to late endosomes/lysosomes (Wall et al., 2015). The trafficking
of IL-6 by IL-6RA could also explain how IL-6 can be readily
secreted after synthesis, with secretory vesicles containing only
a limited number of IL-6 molecules and the majority of IL-6 pro-
ducing cells showing no detectable intracellular pool of IL-6
(Verboogen et al., 2018).
A fourth potential role of co-trafficking of a complex of IL-6
with IL-6RA to the plasma membrane is that it may facilitate
trans-signaling. Trans-signaling is the process by which a com-
plex of (soluble) IL-6RA with IL-6 enables signaling of cells that
do not express IL-6RA (but only gp130) (Taga et al., 1989) and
largely underlies the proinflammatory role of IL-6 (Hunter and
Jones, 2015; Schaper and Rose-John, 2015). Trans-presentation
of IL-6 with IL-6RA on the surface of dendritic cells is respon-
sible for the differentiation of pathogenic Th17 cells (Heink
et al., 2017). Soluble gp130 counteracts this trans-signaling, as
it sequesters the IL-6/IL-6RA complex and prevents it binding to
full-length gp130 (Hunter and Jones, 2015; Schaper and Rose-
John, 2015). IL-6RA in complex with IL-6 can also be cleaved
from the membrane (Mu¨llberg et al., 1993, 1994) by the metal-
loproteases ADAM10 and ADAM17 (Matthews et al., 2003; Yan
et al., 2016; Zunke and Rose-John, 2017). As the Koff rate of IL-6
for IL-6RA is relatively low (Weiergra¨ber et al., 1995), IL-6 will
remain bound to IL-6RA for seconds to minutes after cleavage
and this signaling complex could effectively potentiate cells in
the vicinity. Such a release mechanism would be comparable
with the signaling demonstrated for tumor necrosis factor α
(TNFα), IL-15, and IL-11 (Schmid et al., 1995; Bulfone-Paus
et al., 2006; Mortier et al., 2008; Lokau et al., 2016). For TNFα,
ADAM17 cleaves its precursor at the plasma membrane result-
ing in release of TNFα (Black et al., 1997; Murray and Stow,
2014). The IL-11 receptor (IL-11R) is cleaved by ADAM10, mak-
ing all gp130-positive cells sensitive to IL-11 induced STAT sig-
naling, similar to soluble IL-6RA together with IL-6 (Taga et al.,
1989; Lokau et al., 2016). IL-15 is cleaved at the plasma mem-
brane together with IL-15 receptor subunit alpha (IL-15RA)
(Bergamaschi et al., 2008; Duitman et al., 2008, 2011).
However, in contrast to IL-6 with IL-6RA, IL-15RA is believed to
remain associated with IL-15 and free IL-15 without IL-15RA
does not, or only little, exist in circulation (Duitman et al., 2008,
2011; Bergamaschi et al., 2012).
Based on our data, we propose a fifth role of the intracellular
signaling of IL-6. Our data show that self-activation of pY-STAT3
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by newly synthesized IL-6 (and probably by other factors such
as IL-10 (Melillo et al., 2010)) in transit to the plasma membrane
results in a transient auto-inhibition of further IL-6 transcription
(Figure 7). This negative feedback inhibition is caused by an
antagonistic cross-talk between the LPS–TLR4–p38MAPK and
IL-6–STAT3 pathways (Bode et al., 2012; Meley et al., 2017) and
results in a short-term limit of IL-6 production by the dendritic
cells. Our data show that during sustained exposure to LPS, this
brake in IL-6 production is effectively shut off via the increased
transcription and higher protein presence of SOCS3, which inhi-
bits pY-STAT3 activity (Croker et al., 2003, 2012; Lang et al.,
2003). This transient auto-inhibition of IL-6 synthesis by IL-6 sig-
naling supports a new cellular mechanism by which the immune
system might limit production of excessive IL-6 during sepsis or
the invasion of microbial pathogens into the bloodstream.
Following sepsis, an excessive systemic proinflammatory
response can lead to tissue damage and organ failure and this
so-called septic shock is a main cause of death in intensive care
units (Schulte et al., 2013). IL-6 is a key mediator of septic
shock as low serum levels of IL-6 are associated with a better
prognosis and IL-6 levels in patients with septic shock are high-
er than in patients without shock (Hack et al., 1989; Damas
et al., 1992; Spittler et al., 2000; Chaudhry et al., 2013). In vivo
studies in IL-6-knockout mice demonstrated that LPS adminis-
tration leads to higher levels of proinflammatory cytokines
such as TNFα (Xing et al., 1998) and they do not develop the
hypothermia characteristic of early sepsis and show less
weight loss compared to wild-type mice (Remick et al., 2005).
Moreover, the absence of the IL-6 gene in mouse models of
acute infection decreases inflammatory responses and protects
from mortality and organ failure (Cuzzocrea et al., 1999). In
humans, IL-6 was identified as a key mediator of myocardial
depression in septic shock, which leads to impaired tissue per-
fusion, multi-organ failure, and death (Pathan et al., 2004).
Thus, excessive IL-6 secretion following acute infection can be
detrimental (Tanaka et al., 2016), and the transient restraining
of IL-6 production by self-signaling of newly produced IL-6
might be beneficial.
Figure 7 Self-signaling of IL-6RA at intracellular compartments limits IL-6 synthesis by dendritic cells. Model scheme depicting the interplay
of synthesis, trafficking, and intracellular signaling of IL-6. LPS binding to TLR4 promotes the transcription of IL-6 and SOCS3. SOCS3 is rap-
idly degraded by the proteasome. Newly synthesized IL-6 in transit to the plasma membrane self-signals from endosomal compartments
prior to secretion. Extracellular IL-6 is taken up by the cell and also signals from endosomal compartments. This leads to an increased
pY-STAT3 activation (phosphorylation of Tyr705), which represses the transcription of IL-6. pY-STAT3 activation, in turn, is inhibited by the
increased level of SOCS3. ER, endoplasmic reticulum.
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Materials and methods
MoDCs were derived from peripheral blood monocytes from
healthy volunteers (informed consent obtained and according to
institutional and national ethics guidelines) by culturing with
IL-4 and GM-CSF. Experimental details for the cell culture, PCR,
transfection, western blot, microscopy, and statistical analysis
are described in the Supplementary material.
Supplementary material
Supplementary material is available at Journal of Molecular
Cell Biology online.
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